GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Greenwich Lifesciences Inc (GLSI) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has potential upside based on analyst ratings and clinical trial progress, the lack of immediate positive trading signals, weak financial performance, and recent price decline suggest waiting for clearer entry points or further developments.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 35.162, not signaling oversold or overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 25.544, with key support at 22.733 and resistance at 28.356.
H.C. Wainwright raised the price target to $50 from $39, citing positive efficacy in the Phase 3 FLAMINGO-01 trial for GLSI-100, which reduced breast cancer recurrence by 80% in a specific patient group. This could double the market potential for GLSI-100.
The stock experienced a significant regular market decline of -8.63%. Financial performance remains weak with no revenue and a net loss of -$4.15M in Q3 2025, despite improvements in EPS and net income YoY.
In Q3 2025, the company reported no revenue growth and a net loss of -$4.15M, though net income improved by 55.57% YoY and EPS increased by 50%. Gross margin remains at 0.
H.C. Wainwright maintains a Buy rating and raised the price target to $50, citing highly encouraging clinical trial data that could significantly expand the market for GLSI-100.
